Xenon Pharmaceuticals Inc. Watch

from 8-K 30 pages Amended and Restated 2014 Equity Incentive Plan Xenon Pharmaceuticals Inc. (As Amended Effective June 4, 2024) Article 1 Purpose

from 10-Q 10 pages Form of Performance Share Award Agreement

from 10-K 17 pages December 15, 2023 Confidential via Electronic Mail Re: Third Amended and Restated Employment Agreement

from 10-K 5 pages Consent to Alterations Agreement This Agreement Made Effective as of August 16, 2023 Between Redstone Enterprises Ltd. (“Landlord”) and Xenon Pharmaceuticals Inc

from 10-Q 5 pages Consent to Alterations Agreement This Agreement Made Effective as of March 27, 2023 Between Redstone Enterprises Ltd

from 8-K 10 pages Xenon Pharmaceuticals Inc. Executive Incentive Compensation Plan 1. Purposes of the Plan. the Plan Is Intended to Increase Shareholder Value and the Success of the Company by Motivating Employees to (A) Perform to the Best of Their Abilities and (B) Achieve the Company’s Objectives. 2. Definitions. 2.1. “Actual Award” Means as to Any Performance Period, the Actual Award (If Any) Payable to a Participant for the Performance Period, Subject to the Authority of the Administrator (As Defined in Section 3) Under Section 4.4. 2.2. “Affiliate” Means Any Corporation or Other Entity (Including, but Not Limited To, Partnerships and Joint Ventures) That, From Time to Time and at the Time of Any Determination, Directly or Indirectly, Is in Control of or Is Controlled by the Company. 2.3. “Board” Means the Board of Directors of the Company. 2.4. “Bonus Pool” Means the Pool of Funds Available for Distribution to Participants. Subject to the Terms of the Plan, the Administrator Establishes the Bonus Pool for Each Performance Period. 2.5

from 10-Q 19 pages November 4, 2022 Confidential via Electronic Mail Re: Offer of Employment

from 10-Q 3 pages Consent to Alterations & Lease Modification Agreement This Agreement Made Effective as of May 19, 2022 Between Redstone Enterprises Ltd. (“Landlord”) and Xenon Pharmaceuticals Inc

from 8-K 32 pages Amended and Restated 2014 Equity Incentive Plan Xenon Pharmaceuticals Inc. (As Amended April 20, 2022) Article 1 Purpose

from 10-K 3 pages Neurocrine Biosciences, Inc. 12780 El Camino Real San Diego, California 92130, U.S. Attention: Kyle Gano Dear Kyle, Re: License and Collaboration Agreement Between Xenon Pharmaceuticals Inc. (“Xenon”) and Neurocrine Biosciences, Inc. (“Neurocrine”) Made as of December 2, 2019, as Previously Amended (The “Agreement”) Further to Our Recent Discussions and in Accordance With Section 14.8 of the Agreement, and in Consideration of the Premises and Mutual Covenants Contained Herein, Xenon and Neurocrine Agree as Follows: 1. Letter Amendment #2 Except as Specifically Defined Below, Capitalized Terms Used in This Letter Amendment #2 Shall Have the Same Meaning as Ascribed to Such Terms in the Agreement. 2. Definition

from 8-K 20 pages Share Purchase Agreement

from 8-K 38 pages Lease Agreement

from 10-Q 16 pages August 18, 2021 Confidential via Electronic Mail Re: Offer of Employment

from 8-K 21 pages Share Purchase Agreement

from 10-Q 5 pages Genentech, Inc. 1 Dna Way South San Francisco, Ca 94080 USA Attention: Pharma Partnering, Alliance Management Re: Collaborative Research and License Agreement Between Xenon Pharmaceuticals Inc. (“Xenon”), on the One Hand, and Genentech, Inc. (“Gne”) and F. Hoffmann-La Roche Ltd (“Roche” And, Together With Gne, “Genentech”), Made as of December 22, 2011 (As Amended to Date, the “Agreement”) Dear Sir/Madam: Pursuant to Section 12.3(a)(ii) of the Agreement, Xenon and Genentech Hereby Agree to Terminate the Agreement in Accordance This Letter Agreement. the Capitalized Terms Used but Not Defined in This Letter Agreement Have the Meanings Ascribed to Them in the Agreement. 1. Termination Effective Date the Termination of the Agreement Shall Take Effect on August 6, 2021 (“Termination Date”). 2. Ceased Development

from 10-K 9 pages Lease Extension and Modification Agreement This Agreement Made Effective as of October 5, 2020 Between Redstone Enterprises Ltd. (“Landlord”) and Xenon Pharmaceuticals Inc

from 10-K 12 pages Share Option Agreement

from 8-K 15 pages January 13, 2021 Confidential via Electronic Mail Sherry Aulin Dear Sherry, Re: Employment Agreement

from 8-K 15 pages January 13, 2021 Confidential via Electronic Mail Simon Pimstone Dear Simon, Re: Employment Agreement

from 8-K 15 pages January 13, 2021 Confidential via Electronic Mail Ian Mortimer Dear Ian, Re: Employment Agreement